H
HBK Investments L.P.
+ を保有DMII
+3.13%
3か月リターン
$10.180
-0.010 (-0.10%)終値時点
Loading chart…
- 高値
- 10.190
- 始値
- 10.190
- 出来高加重平均価格
- 10.18
- 出来高
- 1.04M
- 時価総額
- —
- 安値
- 10.180
- 売買代金
- 10.62M
- EV/EBITDA（TTM）
- 0.00
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenue to date.
AI分析 of Drugs Made In America Acquisition II Corp (DMII)
買いDMII appears to be a good buy right now due to its recent positive earnings growth, with net income increasing to 4,396,456 USD in Q2 2026, and a projected final change of +1090.65% based on historical price patterns. However, the current RSI of 33.177 indicates that the stock is oversold, which may present a buying opportunity. The main risk is the high P/E ratio of 49.86, suggesting that the stock may be overvalued if earnings do not continue to grow as expected.
バリュエーション指標
Drugs Made In America Acquisition II Corp（DMII）の現在の予想PERは0.00で、5年平均は0.00です。
DMII を保有するクジラ
DMII のよくある質問 — Alphio AI が回答
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenue to date. It operates in the Financials sector.
DMII appears to be a good buy right now due to its recent positive earnings growth, with net income increasing to 4,396,456 USD in Q2 2026, and a projected final change of +1090.65% based on historical price patterns. However, the current RSI of 33.177 indicates that the stock is oversold, which may present a buying opportunity. The main risk is the high P/E ratio of 49.86, suggesting that the stock may be overvalued if earnings do not continue to grow as expected.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。